Adverse reactions

Table showing summary of adverse reactions observed in ≥10% of patients treated with TECARTUS® in ZUMA-3 (N=78) Table showing summary of adverse reactions observed in ≥10% of patients treated with TECARTUS® in ZUMA-3 (N=78)

ALL=acute lymphoblastic leukemia; R/R=relapsed or refractory.

Reference: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021.

Grade 3 or 4 lab abnormalities

Table showing grade 3 or 4 lab abnormalities occurring in ≥10% of patients treated in ZUMA-3 following TECARTUS® infusion (N=78) Table showing grade 3 or 4 lab abnormalities occurring in ≥10% of patients treated in ZUMA-3 following TECARTUS® infusion (N=78)

Pinch to zoom


Prolonged cytopenias have occurred following treatment with TECARTUS1

  • Patients may exhibit cytopenias for several weeks following lymphodepleting chemotherapy and TECARTUS infusion
  • At Day 30, 20% of patients had unresolved Grade 3 or higher cytopenias
    • 12% with thrombocytopenia
    • 12% with neutropenia

Four Grade 5 adverse reactions occurred with TECARTUS

  • Of the 4 patients who had fatal adverse reactions: one patient with fatal pneumonia had pre-existing pneumonia prior to study enrollment, and one patient with fatal sepsis had prolonged cytopenia and immunosuppression from prior therapies and underlying disease

ALL=acute lymphoblastic leukemia; R/R=relapsed or refractory.

Reference: 1. TECARTUS® (brexucabtagene autoleucel). Prescribing information. Kite Pharma, Inc; 2021.